-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
-
Summary
-
Catalyst Pharmaceuticals, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from 2012 to 2023.
- Catalyst Pharmaceuticals, Inc. Income Tax Expense (Benefit) for the quarter ending June 30, 2024 was $15M, a 39.5% increase year-over-year.
- Catalyst Pharmaceuticals, Inc. Income Tax Expense (Benefit) for the twelve months ending June 30, 2024 was $25.4M, a 13.2% decline year-over-year.
- Catalyst Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2023 was $23.1M, a 6.75% increase from 2022.
- Catalyst Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2022 was $21.6M, a 64.1% increase from 2021.
- Catalyst Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2021 was $13.2M.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Growth (%)